MVRBF - MVRBF STOCK NEWS

Medivir AB announced that IGM Biosciences initiated a clinical study for birinapant (IGM-9427) in solid cancers, combined with IGM's DR5 agonist antibody IGM-8444. This trial aims to assess safety and tolerability, building on promising preclinical results. Following an exclusive licensing agreement in January 2021, Medivir will receive an additional USD 1.5 million as birinapant enters clinical phase I studies. This marks a significant step in the evaluation of birinapant's potential in oncology, as stated by Interim CEO Magnus Christensen.

Medivir AB announced its upcoming presentation at the ProHearings Shared Capital Markets Day on October 14, 2021. The event will be accessible via Medivir's website, ensuring stakeholders can stay informed. Medivir focuses on developing innovative drugs for cancer treatment, highlighting MIV-818, a pro-drug aimed at selectively targeting liver cancer cells to reduce side effects. The company also maintains strategic collaborations, such as its partnership with IGM Biosciences for Birinapant, a treatment for solid tumors. Medivir's shares are listed under the ticker MVIR on Nasdaq Stockholm.

Medivir AB has appointed Malene Jensen as Vice President Clinical Development, effective no later than October 1, 2021. Jensen brings 15 years of experience in Clinical Development, previously at AstraZeneca and Sedana Medical. She will focus on the clinical trials for MIV-818, a drug aimed at liver cancer treatment, which is a priority for Medivir.

The company's strategic direction includes addressing high unmet medical needs in cancer therapy and enhancing patient outcomes.

Medivir AB announced its upcoming presentation at the Redeye Growth Day on June 2, 2021, which will be accessible via live broadcast. The presentation will later be available on Medivir's website. Medivir focuses on developing innovative drugs for cancer treatment, including MIV-818, a pro-drug targeting liver cancer cells. The company emphasizes partnerships in its drug development, notably with IGM Biosciences for the treatment of solid tumors. Medivir's share is listed on the Nasdaq Stockholm Small Cap list under the ticker MVIR.

Medivir AB (Nasdaq Stockholm: MVIR) will present at the ABGSC Life Science Summit on May 25, 2021. Represented by interim CEO Magnus Christensen and Chief Scientific Officer Fredrik Öberg, the presentation will focus on Medivir's innovative cancer drug development, particularly MIV-818, designed to selectively target liver cancer. The presentation will be accessible post-seminar on Medivir's website. Medivir collaborates with partners for drug development, including the exclusive out-licensing of Birinapant to IGM Biosciences for solid tumor treatments.

Medivir AB has appointed Magnus Christensen, the current CFO, as interim CEO effective from the Annual General Meeting on May 5, 2021. This transition follows the departure of Yilmaz Mahshid as CEO at the AGM. Medivir’s Board, led by Chairman Helena Levander, is confident in Christensen's capabilities and has initiated a search for a permanent CEO. Medivir focuses on innovative cancer treatments, with significant developments in drugs like MIV-818 for liver cancer.

Medivir AB announces the availability of its Annual Report for 2020 on its website. Highlights from the report include the progression of MIV-818, a proprietary drug for liver cancer, into phase Ib studies following positive phase Ia results. The company also renegotiated an agreement for birinapant, now licensed to IGM Biosciences, and successfully completed financing to strengthen its investor base. Medivir focuses on drugs targeting high unmet medical needs in cancer treatment.

Medivir AB announced an increase in its share count as of March 2021, following a directed issuance to Linc AB, adding 3,600,000 class B shares. The total share count now stands at 55,735,651, with corresponding voting rights. Medivir focuses on developing innovative cancer therapies, notably MIV-818 for liver cancer, alongside collaborations like Birinapant licensed to IGM Biosciences. The stock is traded under the ticker MVIR on Nasdaq Stockholm.

Medivir AB has appointed Dr. Tom Morris as interim Chief Medical Officer as of October 5, 2020. Dr. Morris, who reports to CEO Yilmaz Mahshid, brings over 20 years of oncology experience from previous roles at Medeval Ltd and AstraZeneca. He has led clinical drug development programs globally and holds multiple degrees including a BSc in Physiology and medical degrees from the University of Wales. This leadership change aims to strengthen Medivir's oncology drug development efforts.